BioDuro Named to Deloitte Technology Fast 500 Asia Pacific 2010 Ranking

13 Jan. 2011


WILMINGTON, N.C., (January 13, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced that BioDuro, A PPD® Company, was named the 22nd fastest-growing technology company in Asia Pacific in the 2010 Deloitte Technology Fast 500 Asia Pacific list of companies.

"BioDuro has continued to invest in world-class laboratories and recruiting and retaining a highly skilled work force that enable us to advance our clients' drug discovery programs," said Andreas Tschirky, Ph.D., leader of BioDuro. "Our drug discovery expertise has created strong revenue growth, and we are honored to be among the prestigious group of companies recognized by Deloitte Asia Pacific."

BioDuro received the honor at the Deloitte Technology Fast 500 Asia Pacific award ceremony held in December in Hong Kong. The Deloitte Technology Fast 500 Asia Pacific recognizes the 500 fastest-growing Asia Pacific-based technology companies. This is the first time BioDuro has been ranked among this prestigious group of companies.

PPD acquired BioDuro in 2009 and employs more than 1,400 in Asia Pacific and nearly 1,000 people in China. It is one of the largest contract research organizations in the country.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the 2010 Deloitte Technology Fast 500 Asia Pacific award and the future growth of BioDuro's drug discovery business, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; success in sales growth; loss of large contracts; increased cancellation rates; the ability to attract and retain key personnel; risks associated with and dependence on collaborative relationships; risks associated with acquisitions and investments, such as impairments; rapid technological advances that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
Tel: +1 919 456 4425

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2019 Pharmaceutical Product Development, LLC. All rights reserved.